Deroy & Devereaux Private Investment Counsel Inc. Cuts Stock Position in Eli Lilly and Company $LLY

Key Points

• Deroy & Devereaux Private Investment Counsel Inc. decreased its stake in Eli Lilly and Company by 16.7%, now holding 2,220 shares valued at approximately $1.73 million.
• The company's recent earnings report revealed $6.31 earnings per share, surpassing estimates by $0.72, with quarterly revenue rising 37.6% year-over-year.
• Analysts have varying opinions on Eli Lilly, with target prices ranging from $715 to $1,028, while maintaining a consensus rating of "Moderate Buy."

Deroy & Devereaux Private Investment Counsel Inc. lessened its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 16.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,220 shares of the company's stock after selling 444 shares during the quarter. Deroy & Devereaux Private Investment Counsel Inc.'s holdings in Eli Lilly and Company were worth $1,731,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Precedent Wealth Partners LLC raised its stake in shares of Eli Lilly and Company by 15.3% in the second quarter. Precedent Wealth Partners LLC now owns 294 shares of the company's stock valued at $229,000 after acquiring an additional 39 shares in the last quarter. Capital Advisors Inc. OK raised its stake in shares of Eli Lilly and Company by 6.8% in the second quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company's stock valued at $5,260,000 after acquiring an additional 429 shares in the last quarter. Family CFO Inc purchased a new position in Eli Lilly and Company in the second quarter valued at $54,000. Duquesne Family Office LLC increased its holdings in Eli Lilly and Company by 52.5% in the first quarter. Duquesne Family Office LLC now owns 94,830 shares of the company's stock valued at $78,321,000 after buying an additional 32,640 shares during the last quarter. Finally, Corient IA LLC purchased a new position in Eli Lilly and Company in the first quarter valued at $570,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $812.65 on Wednesday. The stock's 50-day moving average is $744.36 and its two-hundred day moving average is $765.86. The firm has a market cap of $769.14 billion, a price-to-earnings ratio of 53.11, a PEG ratio of 1.17 and a beta of 0.47. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $935.63. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.59 by $0.72. The company had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business's quarterly revenue was up 37.6% compared to the same quarter last year. During the same quarter last year, the company posted $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Insider Activity

In related news, Director J Erik Fyrwald purchased 1,565 shares of the stock in a transaction that occurred on Tuesday, August 12th. The shares were purchased at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the acquisition, the director directly owned 74,578 shares in the company, valued at $47,903,686.74. This represents a 2.14% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Jamere Jackson purchased 200 shares of the stock in a transaction that occurred on Friday, August 8th. The shares were bought at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the acquisition, the director owned 9,402 shares of the company's stock, valued at approximately $6,013,143.12. The trade was a 2.17% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders have bought 4,514 shares of company stock valued at $2,894,841. Insiders own 0.14% of the company's stock.

Wall Street Analyst Weigh In

LLY has been the topic of several recent analyst reports. Berenberg Bank reissued a "hold" rating and issued a $830.00 target price (down previously from $970.00) on shares of Eli Lilly and Company in a report on Wednesday, September 17th. Morgan Stanley dropped their target price on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an "overweight" rating on the stock in a report on Friday, October 3rd. Leerink Partners reissued a "market perform" rating and issued a $715.00 target price on shares of Eli Lilly and Company in a report on Thursday, August 7th. Leerink Partnrs lowered Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a report on Thursday, August 7th. Finally, HSBC increased their target price on Eli Lilly and Company from $700.00 to $800.00 in a report on Wednesday, October 1st. One research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $948.06.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.